Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niggli

Showing results (491-500 of 516) with videos related to

Pageof 52
Sort By:
Blood Advances|August 8, 2022
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studiesRebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, et al.
Klinische Padiatrie|May 24, 2013
Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000M Schrappe, A Möricke, A Reiter, et al.
Eclinicalmedicine|December 17, 2024
Maintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a multicentre, open-label, randomised controlled phase 3 trialEwa Koscielniak, Gustaf Ljungman, Bernarda Kazanowska, et al.
Blood|January 29, 2021
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studiesMichael U Callaghan, Claude Negrier, Ido Paz-Priel, et al.
Leukemia|February 2, 2008
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemiaT Flohr, A Schrauder, G Cazzaniga, et al.
European Journal of Cancer (Oxford, England : 1990)|October 21, 2019
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 studyAnna Maria Testi, Andishe Attarbaschi, Maria Grazia Valsecchi, et al.
Cancer Medicine|January 18, 2019
Desmoplastic small round cell tumors: Multimodality treatment and new risk factorsMonika Scheer, Christian Vokuhl, Bernd Blank, et al.
Journal of Cancer Research and Clinical Oncology|January 15, 2020
Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS)Monika Scheer, Bernd Blank, Sebastian Bauer, et al.
Haematologica|August 13, 2016
Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescentsAndishe Attarbaschi, Elisa Carraro, Oussama Abla, et al.
The British Journal of Nutrition|February 16, 2016
Composition differences between organic and conventional meat: a systematic literature review and meta-analysisDominika Średnicka-Tober, Marcin Barański, Chris Seal, et al.
Pageof 52

Showing results (491-500 of 516) with videos related to

Sort By:
Pageof 52
Blood Advances|August 8, 2022
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studiesRebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, et al.
Klinische Padiatrie|May 24, 2013
Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000M Schrappe, A Möricke, A Reiter, et al.
Eclinicalmedicine|December 17, 2024
Maintenance therapy with trofosfamide, idarubicin and etoposide in patients with rhabdomyosarcoma and other high-risk soft tissue sarcomas (CWS-2007-HR): a multicentre, open-label, randomised controlled phase 3 trialEwa Koscielniak, Gustaf Ljungman, Bernarda Kazanowska, et al.
Blood|January 29, 2021
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studiesMichael U Callaghan, Claude Negrier, Ido Paz-Priel, et al.
Leukemia|February 2, 2008
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemiaT Flohr, A Schrauder, G Cazzaniga, et al.
European Journal of Cancer (Oxford, England : 1990)|October 21, 2019
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10-14 years as compared with those aged 15-17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 studyAnna Maria Testi, Andishe Attarbaschi, Maria Grazia Valsecchi, et al.
Cancer Medicine|January 18, 2019
Desmoplastic small round cell tumors: Multimodality treatment and new risk factorsMonika Scheer, Christian Vokuhl, Bernd Blank, et al.
Journal of Cancer Research and Clinical Oncology|January 15, 2020
Synovial sarcoma disease characteristics and primary tumor sites differ between patient age groups: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS)Monika Scheer, Bernd Blank, Sebastian Bauer, et al.
Haematologica|August 13, 2016
Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescentsAndishe Attarbaschi, Elisa Carraro, Oussama Abla, et al.
The British Journal of Nutrition|February 16, 2016
Composition differences between organic and conventional meat: a systematic literature review and meta-analysisDominika Średnicka-Tober, Marcin Barański, Chris Seal, et al.
Pageof 52